Are health economics making us sick?

Journal of Nuclear Medicine

Volumn 51, Issue 11, 2010, Pages 1665-1667

  Hicks, Rodney J ^a,b   Borland, Jeff ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL LITERATURE; MEDICAL TECHNOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL TECHNIQUE; THORACOTOMY;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HEALTH; HUMANS; POSITRON-EMISSION TOMOGRAPHY;

EID: 79851473829     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.079772     Document Type: Review

References (25)

1. Schreyögg J, Weller J, Stargardt T, et al. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. J Nucl Med. 2010;51:1668-1675.
2. Adams EJ, Almazan C, Morland B, Bradbury I, King R, Rheinberger P. Joint project of the International Network of Agencies for Health Technology Assessment: Part 2 - Managing the diffusion of positron emission tomography with health technology assessment. Int J Technol Assess Health Care. 2006;22:149-154.
3. Parliament of Australia Senate Web Site. Additional comments by Senator Milne. Available ab: http://www.aph.gov.au/Senate/committee/clac-ctte/pet/ report/d02.htm. Accessed September 8, 2010.
4. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737-743. (Pubitemid 26342476)
5. 18F] fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-511; discussion 511-513.
6. Hicks RJ, Kalff V, MacManus MP, et al. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med. 2001;42:1596-1604. (Pubitemid 33131317)
7. 18F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol. 2001;19:111-118.
8. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 2001;92:886-895. (Pubitemid 32783077)
9. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med. 2002;43:492-499.
10. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002;112:262-268. (Pubitemid 34219438)
11. Ware RE, Matthews JP, Hicks RJ, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck. 2004;26:1008-1017. (Pubitemid 39601219)
12. Scott AM, Gunawardana DH, Kelley B, et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1451-1457.
13. Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. J Nucl Med. 2008;49:1593-1600.
14. Chatterton BE, Ho Shon I, Baldey A, et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:354-361.
15. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol. 2009;112:462-468.
16. Scott AM, Gunawardana DH, Wong J, et al. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging. 2009;36:347-353.
17. Duong CP, Demitriou H, Weih L, et al. Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer. Eur J Nucl Med Mol Imaging. 2006;33:759-769. (Pubitemid 43979683)
18. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol. 2006;103:271-276. (Pubitemid 44374699)
19. Connell CA, Corry J, Milner AD, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck. 2007;29:986-995.
20. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positronemission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507. (Pubitemid 36706537)
21. Dinan MA, Curtis LH, Hammill BG, et al. Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006. JAMA. 2010;303:1625-1631.
22. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359: 1388-1393.
23. Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009;151:221-228, W-248.
24. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys. 2001;50:287-293. (Pubitemid 32472257)
25. Kenny PM, King MT, Viney RC, et al. Quality of life and survival in the 2 years after surgery for non small-cell lung cancer. J Clin Oncol. 2008;26:233-241.